Skip to main content
OpenTrials
Completed

NCT Number: NCT01373853

A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery

This clinical study is a controlled, open, prospective, single-centre, multi-surgeon eye study to determine the safety and efficacy of intraocular cuts for femtosecond laser assisted lens frag-mentation to support phacoemulsification of the cataractous lens prior to IOL implantation. The cuts are applied by means of the FEMTEC femtosecond laser system with the CustomLens soft-ware module using a cylindrical and radial cut pattern with diameter and height dependent on anterior chamber depth, pupil diameter and ocular lens size.

The hypothesis of the study is that by means of femtosecond laser assisted lens fragmentation the required ultrasound energy used for phacoemulsification can be reduced in a safe and effective way.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Maxivision Eye Hospital

Hyderabad, Andhra Pradesh, 500082, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clear corneal media
  • Patients must be at least 18 years of age.

Exclusion criteria

  • On a keratometric map of the cornea, the minimal and maximal K-values of the central 3mm zone must not differ by more than 5 dioptres. (exclusion criterium for Group A only)
  • The maximum K- value may not exceed 60 D, the minimal value may not be smaller than 37 D. (exclusion criterium for Group A only)
  • Corneal disease or pathology that precludes transmission of laser wavelength or distortion of laser light. (exclusion criterium for Group A only)
  • Subjects with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally.
  • Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc.
  • Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye.
  • Known sensitivity to planned concomitant medications.
  • Patients with disorders of the ocular muscle, such as nystagmus or strabismus
  • Keratoconus
  • Patients with woundhealing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses, ocular herpes zoster or simplex, endocrine diseases, lupus, rheumatoid arthritis
  • Abnormal examination results from slit lamp, Fundus, IOL Master
  • Abnormal examination results from Orbscan (exclusion criterium for Group A only)
  • Patients with an autoimmune disease, collagenosis or clinically significant atopy.
  • Patients who are pregnant or nursing.
  • Patients who do not give informed consent.
  • ACD < 2.4 mm or ACD > 4.5 mm as measured by ultrasonic examination (exclusion criterium for Group A only)

Treatment and study plan

Lens Fragmentation by means of a femtosecondlaser

Procedure

In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.

Manual Phacoemulsification

Procedure

Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually

Primary outcomes

  1. Observation of the applied Effective Phaco Time (EPT) for Pahcoemulsifikation during surgery. The observed Effective Phaco Time in Group A should be significantly lower than in group B. Statistically significant difference at p<0.05.

    Time frame: at time of surgery

Secondary outcomes

  1. Less or equal adverse events in Group A compared to group B (e.g. retinal detachment, IOL malposition). p<0.05 will be considered statistically significant.

    Time frame: 1-Day Follow-UP

  2. Less or equal severe adverse events in Group A compared to group B. p<0.05 will be considered statistically significant.

    Time frame: 1-Day Follow-UP

  3. Easy of phacoemulsification as subjectively perceived by the surgeon during surgery

    Time frame: time fo surgery

Sponsors and collaborators

Lead sponsor

Technolas Perfect Vision GmbH

Industry

Registry information

Acronym: 1103

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Jun 15, 2011
Registry last updated
May 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.